Anika Therapeutics ANIK Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's accrued expenses and other liabilities?
- Anika Therapeutics (ANIK) reported accrued expenses and other liabilities of $14.63M in Q1 2026.
- How has Anika Therapeutics's accrued expenses and other liabilities changed year-over-year?
- Anika Therapeutics's accrued expenses and other liabilities increased by 15.9% year-over-year, from $12.62M to $14.63M.
- What is the long-term trend for Anika Therapeutics's accrued expenses and other liabilities?
- Over 5 years (2020 to 2025), Anika Therapeutics's accrued expenses and other liabilities has grown at a 1.4% compound annual growth rate (CAGR), from $14.79M to $15.87M.